Top

Published in:

01-08-2019 | Breast Cancer | Epidemiology

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

Authors: Hua Zhao, Jie Shen, Steven C. Moore, Yuanqing Ye, Xifeng Wu, Francisco J. Esteva, Debasish Tripathy, Wong-Ho Chow

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

The metabolic etiology of breast cancer has been explored in the past several years using metabolomics. However, most of these studies only included non-Hispanic White individuals.

Methods

To fill this gap, we performed a two-step (discovery and validation) metabolomics profiling in plasma samples from 358 breast cancer patients and 138 healthy controls. All study subjects were either Hispanics or non-Hispanic African Americans.

Results

A panel of 14 identified metabolites significantly differed between breast cancer cases and healthy controls in both the discovery and validation sets. Most of these identified metabolites were lipids. In the pathway analysis, citrate cycle (TCA cycle), arginine and proline metabolism, and linoleic acid metabolism pathways were observed, and they significantly differed between breast cancer cases and healthy controls in both sets. From those 14 metabolites, we selected 9 non-correlated metabolites to generate a metabolic risk score. Increased metabolites risk score was associated with a 1.87- and 1.63-fold increased risk of breast cancer in the discovery and validation sets, respectively (Odds ratio (OR) 1.87, 95% Confidence interval (CI) 1.50, 2.32; OR 1.63, 95% CI 1.36, 1.95).

Conclusions

In summary, our study identified metabolic profiles and pathways that significantly differed between breast cancer cases and healthy controls in Hispanic or non-Hispanic African American women. The results from our study might provide new insights on the metabolic etiology of breast cancer.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Yedjou CG, Tchounwou PB, Payton M, Miele L, Fonseca DD, Lowe L, Alo RA (2017) Assessing the racial and ethnic disparities in breast cancer mortality in the United States. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph14050486 CrossRefPubMedPubMedCentral

Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH (2012) Metabolomics in cancer: a bench-to-bedside intersection. Crit Rev Oncol Hematol 84(1):1–7. https://doi.org/10.1016/j.critrevonc.2012.02.009 CrossRefPubMed

Yu B, Zheng Y, Alexander D, Morrison AC, Coresh J, Boerwinkle E (2014) Genetic determinants influencing human serum metabolome among African Americans. PLoS Genet. https://doi.org/10.1371/journal.pgen.1004212 CrossRefPubMedPubMedCentral

Playdon MC, Ziegler RG, Sampson JN, Stolzenberg-Solomon R, Thompson HJ, Irwin ML, Mayne ST, Hoover RN, Moore SC (2017) Nutritional metabolomics and breast cancer risk in a prospective study. Am J Clin Nutr 106(2):637–649. https://doi.org/10.3945/ajcn.116.150912 CrossRefPubMedPubMedCentral

Moore SC, Playdon MC, Sampson JN, Hoover RN, Trabert B, Matthews CE, Ziegler RG (2018) A metabolomics analysis of body mass index and postmenopausal breast cancer risk. J Natl Cancer Inst 110(6):588–597. https://doi.org/10.1093/jnci/djx244 CrossRefPubMedPubMedCentral

Shen J, Yan L, Liu S, Ambrosone CB, Zhao H (2013) Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes. Transl Oncol 6(6):757–765. https://doi.org/10.1593/tlo.13619 CrossRefPubMedPubMedCentral

Hart CD, Vignoli A, Tenori L, Uy GL, To TV, Adebamowo C, Hossain SM, Biganzoli L, Risi E, Love RR, Luchinat C, Di Leo A (2017) Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicenter population. Clin Cancer Res 23(6):1422–1431. https://doi.org/10.1158/1078-0432.Ccr-16-1153 CrossRefPubMedPubMedCentral

Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, Fornier M, Hudis C, Norton L, Luchinat C, Di Leo A (2015) Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol 9(1):128–139. https://doi.org/10.1016/j.molonc.2014.07.012 CrossRefPubMed

10.

Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, Fornier M, Morris PG, Biganzoli L, Luchinat C, Bertini I, Di Leo A (2011) Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol 22(6):1295–1301. https://doi.org/10.1093/annonc/mdq606 CrossRefPubMed

11.

Asiago VM, Alverado LZ, Shanaiah N, Gowda NG, Owusu-Sarfo K, Ballas R, Raftery D (2010) Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. https://doi.org/10.1158/0008-5472.Sabcs10-P3-10-18 CrossRefPubMedPubMedCentral

12.

Zhang AH, Sun H, Qiu S, Wang XJ (2013) Metabolomics in noninvasive breast cancer. Clin Chim Acta 424:3–7. https://doi.org/10.1016/j.cca.2013.05.003 CrossRefPubMed

13.

Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S, Musharraf SG (2017) Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas chromatography-mass spectrometry. Sci Rep. https://doi.org/10.1038/s41598-017-01924-9 CrossRefPubMedPubMedCentral

14.

Khodadadi-Jamayran A, Akgol-Oksuz B, Afanasyeva Y, Heguy A, Thompson M, Ray K, Giro-Perafita A, Sanchez I, Wu X, Tripathy D, Zeleniuch-Jacquotte A, Tsirigos A, Esteva FJ (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9(16):12868–12878. https://doi.org/10.18632/oncotarget.24403 CrossRefPubMedPubMedCentral

15.

Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81(16):6656–6667. https://doi.org/10.1021/ac901536h CrossRefPubMed

16.

DeHaven CD, Evans AM, Dai HP, Lawton KA (2010) Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform. https://doi.org/10.1186/1758-2946-2-9 CrossRefPubMedPubMedCentral

17.

Sampson JN, Boca SM, Shu XO, Stolzenberg-Solomon RZ, Matthews CE, Hsing AW, Tan YT, Ji BT, Chow WH, Cai QY, Liu DK, Yang G, Xiang YB, Zheng W, Sinha R, Cross AJ, Moore SC (2013) Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidem Biomar 22(4):631–640. https://doi.org/10.1158/1055-9965.Epi-12-1109 CrossRef

18.

Chong EY, Huang Y, Wu H, Ghasemzadeh N, Uppal K, Quyyumi AA, Jones DP, Yu T (2015) Local false discovery rate estimation using feature reliability in LC/MS metabolomics data. Sci Rep 5:17221. https://doi.org/10.1038/srep17221 CrossRefPubMedPubMedCentral

19.

Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A (2013) HMDB 3.0—the human metabolome database in 2013. Nucleic Acids Res 41(Database issue):D801–D807. https://doi.org/10.1093/nar/gks1065 CrossRefPubMed

20.

Chong J, Xia JG (2018) MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34(24):4313–4314. https://doi.org/10.1093/bioinformatics/bty528 CrossRefPubMedPubMedCentral

21.

Moore SC, Matthews CE, Sampson JN, Stolzenberg-Solomon RZ, Zheng W, Cai Q, Tan YT, Chow WH, Ji BT, Liu DK, Xiao Q, Boca SM, Leitzmann MF, Yang G, Xiang YB, Sinha R, Shu XO, Cross AJ (2014) Human metabolic correlates of body mass index. Metabolomics 10(2):259–269. https://doi.org/10.1007/s11306-013-0574-1 CrossRefPubMed

22.

Zhao H, Shen J, Djukovic D, Daniel-MacDougall C, Gu H, Wu X, Chow WH (2016) Metabolomics-identified metabolites associated with body mass index and prospective weight gain among Mexican American women. Obes Sci Pract 2(3):309–317. https://doi.org/10.1002/osp4.63 CrossRefPubMedPubMedCentral

23.

Rodriguez-Enriquez S, Hernandez-Esquivel L, Marin-Hernandez A, El Hafidi M, Gallardo-Perez JC, Hernandez-Resendiz I, Rodriguez-Zavala JS, Pacheco-Velazquez SC, Moreno-Sanchez R (2015) Mitochondrial free fatty acid beta-oxidation supports oxidative phosphorylation and proliferation in cancer cells. Int J Biochem Cell B 65:209–221. https://doi.org/10.1016/j.biocel.2015.06.010 CrossRef

24.

Nieman KM, Romero IL, Van Houten B, Lengyel E (2013) Adipose tissue and adipocytes support tumorigenesis and metastasis. BBA Mol Cell Biol Lipids 1831(10):1533–1541. https://doi.org/10.1016/j.bbalip.2013.02.010 CrossRef

25.

Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, Somlo G, Jandial R, Ann D, Hanash S, Jove R, Yu H (2018) JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 27(1):136–150 e135. https://doi.org/10.1016/j.cmet.2017.11.001 CrossRefPubMed

26.

Kinlaw WB, Baures PW, Lupien LE, Davis WL, Kuemmerle NB (2016) Fatty acids and breast cancer: make them on site or have them delivered. J Cell Physiol 231(10):2128–2141. https://doi.org/10.1002/jcp.25332 CrossRefPubMedPubMedCentral

27.

Cui M, Wang QL, Chen G (2016) Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients. Biomed Chromatogr 30(1):42–47. https://doi.org/10.1002/bmc.3556 CrossRefPubMed

28.

O’Flaherty JT, Wooten RE, Samuel MP, Thomas MJ, Levine EA, Case LD, Akman SA, Edwards IJ (2013) Fatty acid metabolites in rapidly proliferating breast cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0063076 CrossRefPubMedPubMedCentral

29.

Zhang H, Zhou L, Shi W, Song N, Yu K, Gu Y (2012) A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer. Int J Mol Med 30(3):487–494. https://doi.org/10.3892/ijmm.2012.1022 CrossRefPubMedPubMedCentral

30.

Li J, Humphreys K, Heikkinen T, Aittomaki K, Blomqvist C, Pharoah PD, Dunning AM, Ahmed S, Hooning MJ, Martens JW, van den Ouweland AM, Alfredsson L, Palotie A, Peltonen-Palotie L, Irwanto A, Low HQ, Teoh GH, Thalamuthu A, Easton DF, Nevanlinna H, Liu J, Czene K, Hall P (2011) A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126(3):717–727. https://doi.org/10.1007/s10549-010-1172-9 CrossRefPubMed

31.

Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH (2017) Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544(7650):372–376. https://doi.org/10.1038/nature22056 CrossRefPubMed

32.

Heber D, Byerly LO, Chlebowski RT (1985) Metabolic abnormalities in the cancer patient. Cancer 55 (1):225–229CrossRefPubMed

33.

Bi X, Henry CJ (2017) Plasma-free amino acid profiles are predictors of cancer and diabetes development. Nutr Diabetes 7(3):e249. https://doi.org/10.1038/nutd.2016.55 CrossRefPubMedPubMedCentral

34.

Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, Saruki N, Bando E, Kimura H, Imamura F, Moriyama M, Ikeda I, Chiba A, Oshita F, Imaizumi A, Yamamoto H, Miyano H, Horimoto K, Tochikubo O, Mitsushima T, Yamakado M, Okamoto N (2011) Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 6(9):e24143. https://doi.org/10.1371/journal.pone.0024143 CrossRefPubMedPubMedCentral

35.

Quevedo-Coli S, Crespi C, Benito E, Palou A, Roca P (1997) Alterations in circulating fatty acids and the compartmentation of selected metabolites in women with breast cancer. Biochem Mol Biol Int 41(1):1–10PubMed

36.

Kuhn T, Sookthai D, Graf ME, Schubel R, Freisling H, Johnson T, Katzke V, Kaaks R (2017) Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study. Br J Cancer 117(10):1572–1579. https://doi.org/10.1038/bjc.2017.313 CrossRefPubMedPubMedCentral

37.

Liu XA, Meng QH, Ye YQ, Hildebrandt MAT, Gu J, Wu XF (2015) Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis 36(2):243–248. https://doi.org/10.1093/carcin/bgu247 CrossRefPubMed

38.

Srivastava P, Hira SK, Srivastava DN, Gupta U, Sen P, Singh RA, Manna PP (2017) Protease-responsive targeted delivery of doxorubicin from bilirubin-BSA-capped mesoporous silica nanoparticles against colon cancer. ACS Biomater Sci Eng 3(12):3376–3385. https://doi.org/10.1021/acsbiomaterials.7b00635 CrossRefPubMed

39.

Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I (2011) Serum Bilirubin and Risk of Respiratory Disease and Death. Jama-J Am Med Assoc 305(7):691–697. doi:https://doi.org/10.1001/jama.2011.124 CrossRef

40.

Wen CP, Zhang FM, Liang D, Wen C, Gu J, Skinner H, Chow WH, Ye YQ, Pu X, Hildebrandt MAT, Huang MS, Chen CH, Hsiung CA, Tsai MK, Tsao CK, Lippman SM, Wu XF (2015) The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res 21(1):193–200. https://doi.org/10.1158/1078-0432.Ccr-14-0748 CrossRefPubMed

41.

Temme EHM, Zhang JJ, Schouten EG, Kesteloot H (2001) Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Cause Control 12(10):887–894. doi:Doi 10.1023/A:1013794407325CrossRef

42.

Yadava N, Schneider SS, Jerry DJ, Kim C (2013) Impaired mitochondrial metabolism and mammary carcinogenesis. J Mammary Gland Biol 18(1):75–87. https://doi.org/10.1007/s10911-012-9271-3 CrossRef

43.

Ahn CS, Metallo CM (2015) Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. https://doi.org/10.1186/s40170-015-0128-2 CrossRefPubMedPubMedCentral

44.

Grzybowska-Szatkowska L, Rzymowska J, Slaska B (2016) Oxidative phosphorylation genes in breast cancer cells. Int J Mol Med 38:S78–S78

45.

Marini C, Bianchi G, Buschiazzo A, Ravera S, Martella R, Bottoni G, Petretto A, Emionite L, Monteverde E, Capitanio S, Inglese E, Fabbi M, Bongioanni F, Garaboldi L, Bruzzi P, Orengo AM, Raffaghello L, Sambuceti G (2016) Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Sci Rep. https://doi.org/10.1038/srep19569 CrossRefPubMedPubMedCentral

46.

Meric-Bernstam F, Evans K, Zheng XF, Su XP, Yuca E, Scott S, Akcakanat A, Ueno N, Lim B, Litton J, Valero V, Symmans F, Hortobagyi G, Perou C, Tripathy D, Draetta G, Marszalek J, Gonzalez-Angulo AM, Moulder S (2017) Oxidative phosphorylation as a target in triple negative breast cancer therapy. Cancer Res. https://doi.org/10.1158/1538-7445.Am2017-4970 CrossRefPubMedPubMedCentral

47.

Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, Grammatico P (2008) Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat 110(3):439–452. https://doi.org/10.1007/s10549-007-9738-x CrossRefPubMed

48.

Phang JM, Liu W, Hancock CN, Fischer JW (2015) Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr 18(1):71–77. https://doi.org/10.1097/Mco.0000000000000121 CrossRef

49.

Elia I, Broekaert D, Christen S, Boon R, Radaelli E, Orth MF, Verfaillie C, Grunewald TGP, Fendt SM (2017) Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. https://doi.org/10.1038/ncomms15267 CrossRefPubMedPubMedCentral

50.

Mouradian M, Kikawa KD, Dranka BP, Komas SM, Kalyanaraman B, Pardini RS (2015) Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. Mol Carcinogen 54(9):810–820. https://doi.org/10.1002/mc.22151 CrossRef

51.

Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE (2010) Metabolic signatures of exercise in human plasma. Sci Transl Med 2(33):33ra37. https://doi.org/10.1126/scitranslmed.3001006 CrossRefPubMedPubMedCentral

Title: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women
Authors: Hua Zhao
Jie Shen
Steven C. Moore
Yuanqing Ye
Xifeng Wu
Francisco J. Esteva
Debasish Tripathy
Wong-Ho Chow
Publication date: 01-08-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05165-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis

Effects of tea consumption and the interactions with lipids on breast cancer survival

Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer

Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer

Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer